The Lancet in conversation with

The Lancet Group
  • 0.0 (0)
  • MEDICINE
  • UPDATED FORTNIGHTLY

Jessamy Bagenal, Chloe Wilson, and Callum Davidson—editors at The Lancet—and Gavin Cleaver, The Lancet Group’s Audio Producer, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.  A monthly audio companion to the journal, this podcast covers topics that advance the field of medical research, from exploring treatments to examining drug trials, public health outbreaks to surgical techniques, and more.

  1. 19/12/2025

    Susannah Stanway on the London Global Cancer Week

    In Conversation with The Lancet returns with Dr Susannah Stanway, honorary consultant medical oncologist at the Royal Marsden and honorary clinical senior lecturer in Education at the Institute of Cancer Research, reflecting on London Global Cancer Week 2025. This episode goes beyond event highlights to discuss the need for a global oncology agenda rooted in equity, evidence-based care, and value across care settings. Topics span from geriatric oncology to cardio-oncology, nursing workforce resilience, cancer care in conflict zones, and sustainable health financing, showing how multi-stakeholder collaboration can drive policy and practical improvements, especially in low- and middle-income countries. Listeners will take away practical steps for action: integrating geriatric assessment and baseline cardiovascular risk checks, strengthening cancer registries and national audits, and pursuing domestic funding for universal health coverage. The discussion highlights the urgency of addressing cancer globally including context specific solutions sensitive to local settings and emphasises prevention, early diagnosis, and accessible treatment as core priorities. Click here to visit the London Global Cancer week website Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    24 min

  2. 09/12/2025

    Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health

    Ultra-processed foods are on the rise. Despite the emphasis placed on individual responsibility, our deteriorating diets are primarily the result of the sophisticated political tactics of a powerful global ultra-processed food industry. Addressing this urgent threat demands a coordinated response from the global public health community. So argues a 3-paper Series published in The Lancet that examines the evidence, proposes policies to halt and reverse the rise in ultra-processed foods, and illuminates the fundamental political and economic drivers at play. Professor Carlos Monterio, Professor Camila Corvalán, and Professor Phil Baker join host Callam Davidson to discuss this powerful and timely Series. Click here to visit the series hub: https://www.thelancet.com/series-do/ultra-processed-food Download the 'Lancet Series on Ultra-Processed Foods and Human Health' infographic here: https://www.thelancet.com/infographics-do/ultra-processed-food-2025 Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    1h 1m

  3. 07/12/2025

    Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma

    Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02360-8/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    13 min

  4. 19/10/2025

    Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC

    Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    21 min

  5. 17/10/2025

    Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer

    Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    22 min

  6. 28/07/2025

    Stephen Chan on the Lancet Commission on addressing the global hepatocellular carcinoma burden

    With the global burden of liver cancer growing, The Lancet has commissioned an international panel of experts to identify strategies to strengthen the prevention, surveillance, diagnosis, and treatment of liver cancer. Stephen Chan joins Ben Abbott of The Lancet to discuss the key messages of the Commission, which is published today on World Hepatitis Day. Read the full Commission: https://www.thelancet.com/commissions-do/hepatocellular-carcinoma?dgcid=buzzsprout_icw_podcast_lancethcc25_lancet Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    21 min

  7. 24/07/2025

    Rebecca Fitzgerald on biomarker risk stratification with capsule sponge in the surveillance of Barrett's oesophagus

    Early detection of oesophageal adenocarcinoma improves outcomes. Patients with the precursor lesion, Barrett's oesophagus, are recommended to undergo regular endoscopic surveillance, a process that can be burdensome for patients and health services.  Professor Rebecca Fitzgerald's team have developed a tool that may be able to improve Barrett's surveillance. She joins us to discuss her recent prospective real-world implementation study of capsule sponge risk stratification in Barrett’s oesophagus surveillance in the UK. Read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01021-9/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lancet Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    27 min

  8. 11/06/2025

    ASCO 2025 Debrief

    Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, and Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference.  If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167 Articles discussed in this podcast episode include: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlw Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlw Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlw #asco2025 Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    15 min
See All (38)

About

Jessamy Bagenal, Chloe Wilson, and Callum Davidson—editors at The Lancet—and Gavin Cleaver, The Lancet Group’s Audio Producer, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.  A monthly audio companion to the journal, this podcast covers topics that advance the field of medical research, from exploring treatments to examining drug trials, public health outbreaks to surgical techniques, and more.

Information

More From The Lancet Group

You Might Also Like